1. Signaling Pathways
  2. GPCR/G Protein
  3. Platelet-activating Factor Receptor (PAFR)
  4. Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonists (27):

Cat. No. Product Name Effect Purity
  • HY-N0784
    Ginkgolide B
    Antagonist 99.96%
    Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.
  • HY-N2071
    Cedrol
    Antagonist ≥98.0%
    Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
  • HY-N12995
    α-Bulnesene
    Antagonist
    α-Bulnesene is a novel PAF receptor antagonist with the IC50 of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation.
  • HY-19126
    CL-184005
    Antagonist
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis.
  • HY-N0784R
    Ginkgolide B (Standard)
    Antagonist
    Ginkgolide B (Standard) is the analytical standard of Ginkgolide B. This product is intended for research and analytical applications. Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.
  • HY-N10663
    Kadsurenone
    Antagonist ≥99.0%
  • HY-N3436
    Kadsurin A
    Antagonist
    Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor.
  • HY-132190
    Hexanolamino PAF C-16
    Antagonist
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation.
  • HY-121377
    Epiyangambin
    Antagonist
    Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).
  • HY-163101
    CP-96021
    Antagonist
    CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma.
  • HY-116120
    N-Acetyldesloratadine
    Antagonist 99.93%
    N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC50 of 0.6 µM.
  • HY-W700638A
    Benafentrine maleate
    Antagonist
    Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor.
  • HY-106837
    Israpafant
    Antagonist
    Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice.
  • HY-101654
    Rocepafant
    Antagonist
    Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research.
  • HY-106833A
    SDZ-62-434
    Antagonist
    SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies.
  • HY-123399
    Ro 19-1400
    Antagonist
    Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.
  • HY-124887
    L 651142
    Antagonist
    L 651142 is a weak platelet activating factor (PAF) receptor antagonist. L 651142 inhibits the binding of [3H]PAF to rabbit platelet, human platelet or human lung membranes with Kis of 0.839 μM, 1.82 μM, 3.64 μM, respectively.
  • HY-106038
    Acopafant
    Antagonist
    Acopafant (Dacopafant; RP 55778) is a potent platelet-activating factor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection.
  • HY-N7343
    Pregomisin
    Antagonist
    Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC50 values were 48 μM.
  • HY-123505
    Dersalazine sodium
    Antagonist
    Dersalazine (sodium) is a platelet-activating factor (PAF) antagonist. Dersalazine (sodium) can exert intestinal anti-inflammatory activity in rodent colitis models by downregulating IL-17 expression.